A Research Study on Etavopivat in Participants With and Without Liver Disease
← catalyst calendarSponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
48actual
Sites
5
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-05-20 | actual | When the study began enrolling |
| Primary completion | 2025-08-01 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-08-01 | actual | The whole study's end, after follow-up |
| First posted | 2024-03-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Liver Diseases
Intervention
- Drug: Etavopivat
Primary outcomes
what the primary-completion date above is the date OFArea under the etavopivat plasma concentration-time curve from 0 hours and extrapolated to infinity after a single dose (AUC0-inf, etavopivat)
measured From IMP administration on day 1 to completion of the end of study visit (day 9)
Maximum observed etavopivat plasma concentration after a single dose (Cmax, etavopivat)
measured From IMP administration on day 1 to completion of the end of study visit (day 9)
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed